EPO Revokes Controversial Patent For Breast Cancer Screening

Law360, New York (May 19, 2004, 12:00 AM EDT) -- The European Patent Office has revoked U.S. biotechnology company Myriad Genetics’ European patent on a controversial breast cancer genetic test that critics claim is excessively expensive.

The patent covers a test to predict if a woman is at high risk of developing breast cancer by looking for mutations in a gene called BRCA1.

“After a public hearing of all parties to the opposition proceedings against the patent, the division - a panel composed of three patent examiners and a legal expert - concluded that the grounds...
To view the full article, register now.